ArticleMolecular therapy. Nucleic acids2026
miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor pathological response to neoadjuvant chemoradiotherapy (neo-CRT) remains a major clinical challenge in esophageal adenocarcinoma (EAC), contributing to treatment resistance and poor patient outcomes. Identification of novel predictive biomarkers of treatment resistance and therapeutic targets to enhance treatment response are crucial to improving patient outcomes. In this study, we investigated the role of miR-34a-5p in EAC treatment response using both cell line models and clinical tumor samples. We observed reduced miR-34a-5p expression across multiple cell line models of radioresistant EAC. Overexpression of miR-34a-5p enhanced radiosensitivity, impaired DNA damage repair, and altered cell cycle following irradiation, accompanied by changes in the expression of DNA damage response and cell cycle-related genes. Consistent with these findings, analysis of pre-treatment tumor biopsies from EAC patients demonstrated that reduced miR-34a-5p expression was associated with poor response to neo-CRT, advanced pathological T stage, and worse clinical outcomes. This study demonstrates for the first time, a role for miR-34a-5p as a potential biomarker of treatment response and an independent predictor of survival outcomes in EAC patients. Furthermore, we identify miR-34a-5p as a radiosensitizer in EAC, highlighting a novel therapeutic approach to enhance the efficacy of radiation therapy in EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.